Publications by authors named "Jihan Aarab"

3 Publications

  • Page 1 of 1

Lacrimal gland adenoid cystic carcinoma: report of an unusual case with literature review.

Radiat Oncol J 2021 Jun 28;39(2):152-158. Epub 2021 Jun 28.

Department of Radiation Oncology, National Institute of Oncology, Rabat, Morocco.

Lacrimal gland adenoid cystic carcinomas are rare, aggressive orbital tumors characterized by poor overall prognosis, tendency for local recurrence and metastasis despite aggressive treatment. Treatment continues to be controversial. Many authorities today will often initiate surgery (orbital exenteration with or without bone removal vs. globe-sparing resection) and adjuvant radiotherapy (external beam or proton beam therapy). We introduce a case of lacrimal gland adenoid cystic carcinoma treated with orbital exenteration and adjuvant volumetric modulated arc therapy, and discuss the related literature.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.3857/roj.2021.00122DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8497861PMC
June 2021

Intrathyroidal parathyroid carcinoma: a case report and literature review.

Radiat Oncol J 2021 Jun 24;39(2):145-151. Epub 2021 Mar 24.

Department of Radiation Oncology, National Institute of Oncology, Rabat, Morocco.

Parathyroid carcinoma is an uncommon endocrine malignancy comprising 0.5%-2% of patients with primary hyperparathyroidism. The probability of an intrathyroidal location is low (0.2%) and make preoperative suspicion and diagnosis challenging. Less than 20 cases of intrathyroidal parathyroid carcinoma have been reported. We introduce a case of intrathyroidal parathyroid carcinoma mimicking a suspicious thyroid nodule, and review the literature, with a focus on the role of adjuvant radiotherapy.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.3857/roj.2020.01060DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8497858PMC
June 2021

Hypofractionated Regional Nodal Irradiation for Women With Node-Positive Breast Cancer.

Int J Radiat Oncol Biol Phys 2017 03 15;97(3):563-570. Epub 2016 Nov 15.

Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat, Morocco.

Purpose: To evaluate the effect of hypofractionated radiation therapy (HFRT) of the breast/chest wall and regional nodes on overall survival (OS), disease-free survival (DFS), locoregional control and on treatment-related toxicity in patients with breast cancer and nodal involvement.

Methods And Materials: Two hundred fifty-seven patients treated between October 2009 and June 2011 with hypofractionated locoregional radiation therapy (42 Gy in 15 fractions) were retrospectively reviewed, 51 (19.8%) after breast-conserving surgery and 206 (80.2%) after radical surgery. Patients treated with breast-conserving surgery received a boost dose to the tumor bed (delivered by photons, electrons, or interstitial high-dose-rate brachytherapy). Two hundred fifty-six (99.6%) patients underwent chemotherapy, 209 (81.3%) had hormonal treatment, and 65 (25.3%) had anti-HER2 targeted therapy.

Results: The median follow-up time was 64 months (range, 11-88 months). The rates of 5-year OS, DFS, locoregional recurrence (LRR)-free survival, and distant metastasis (DM)-free survival were 86.6%, 84.4%, 93.9%, and 83.1%, respectively. In multivariate analysis (MVA), lymph node ratio >65%, lymphovascular invasion, and negative hormone receptor status predicted for OS, DSF, and DM. T3 to 4 stage was also associated with worse DFS and DM. Finally, for LRR the independent prognostic factors on MVA were N2 to 3 stage and grade 3. Hyperpigmentation was observed in 19.2% of patients, telangiectasia in 12.3%, and fibrosis in 30.7%. Grade ≥2 lymphedema was recorded in 5.8% of cases. During the study follow-up, no cardiac or symptomatic pneumonitis was observed, nor were plexopathy or rib fractures.

Conclusion: According to the findings from this retrospective study, HFRT seems to be an acceptable alternative for patients with breast cancer who need regional nodal irradiation. However, prospective randomized trials are necessary to confirm these preliminary results.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2016.11.010DOI Listing
March 2017
-->